Related Experiment Video
Updated: Sep 20, 2025

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
Published on: June 8, 2021
GLP-1 Agonists for Pediatric Psychopharmacology: Opportunities and Cautions
Michael Bartkoski1,2, Ethan A Poweleit1, Stephani L Stancil1,2,3
1Division of Clinical Pharmacology, Toxicology, & Therapeutic Innovation, Department of Pediatrics, Children's Mercy Kansas City, Kansas City, Missouri, USA.
Abstract:
Glucagon-like peptide-1 agonists (GLP-1A) are increasingly prescribed to treat obesity and type 2 diabetes mellitus in children and adolescents. Emerging evidence suggesting neuropsychiatric effects presents an opportunity for pediatric psychopharmacology but requires careful consideration of potential adverse effects and risk of misuse. This perspective examines potential applications and cautions surrounding GLP-1As for pediatric mental health, particularly substance use, depression, and eating disorders, and advocates for research and clinical monitoring to ensure their safety and efficacy.
More Related Videos
06:38Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
Published on: June 11, 2017
07:35Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans
Published on: February 4, 2014
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Drug Therapy
Antianxiety Medications
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Psychosis: Goals of Pharmacotherapy
Oral Hypoglycemic Agents: Glinides
Factors Affecting Drug Response: Overview